Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian marketAsia accounts for nearly two-thirds of lung cancer cases worldwidebioAffinity Technologies, Inc. (NASDAQ:BIAF,
bioAffinity got permission to use its lung cancer test in Hong Kong and China. This helps the company sell its technology to more patients in Asia, where lots of people get lung cancer.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.